
    slow accrual
  
['breast carcinoma']
['celecoxib']

        Inclusion Criteria:

          -  Participants must have biopsy proven invasive breast carcinoma stages T1cN0 to T3N0,
             ER or PR positive with tumors greater than 1cm without lymph node spread.

          -  Participants must have a mammographic breast composition category (density) of c or d.

          -  Participants must be willing to participate and provide signed informed consent.

          -  Participants must have no immediate requirements for chemotherapy, radiotherapy or
             hormonal therapy.

          -  Participants must be willing to discontinue any use of NSAIDs like aspirin or
             ibuprofen until the tumor is removed

          -  Participants cannot be taking the following medications because of major
             pharmacokinetic interactions with celecoxib while being enrolled in the study:
             Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole,
             Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine,
             Ticlopidine, Tirofiban, Vilazodone and Warfarin.

          -  Participants should pass MRI screening questionnaire

        Exclusion Criteria:

          -  Prior history of cancer, neo-adjuvant chemotherapy and radiation therapy

          -  No daily NSAIDs intake within the past 4 weeks. Intermittent non-daily NSAIDs is
             allowed under PI discretion.

          -  Current or prior systemic use of corticosteroids in the past month.

          -  Participants with history of hypertension, congestive heart failure, edema, stroke or
             other cardiac disease or condition.

          -  Participants with type 2 diabetes, documented stomach ulcers and pulmonary embolism.

          -  Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction,
             sulfonamide allergy

          -  Participants who are currently pregnant

          -  Participants with known human immunodeficiency virus (HIV) infection, hepatitis B
             carrier state or with clinical evidence of hepatitis B.

          -  Participants who are not able to understand or provide written informed consent.

          -  Participants with standard contraindications to non-contrast MRI will be excluded,
             including claustrophobia and metallic implants incompatible with MRI.

          -  Participants whose girth exceeds the bore of the MRI scanner.

          -  Participants requiring conscious sedation for MR imaging.
      